Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Stage III Colon Cancer
NCT02664077Phase 3Terminated
- Sponsor
- NSABP Foundation
- Start
- Jun 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of regorafenib in colon cancer, sponsored by NSABP Foundation. Started Jun 2016; status: terminated.
02
Drugs
regorafenib
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT02664077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02664077.